Dr. Prasad Adusumilli

Co-Director of Mesothelioma Program at Memorial Sloan Kettering Cancer Center

Dr. Prasad Adusumilli is Co-Director of one of the top mesothelioma cancer centers in the world. He is experienced with pleurectomy/decortication surgery and also investigates other therapies through clinical trials.

doctor image

focus icon

Pleural Mesothelioma

location icon

Memorial Sloan Kettering Cancer Center

1275 York Avenue, New York, NY 10065

doctor image


jump to icon


More Information About Mesothelioma Specialist Dr. Prasad Adusumilli

Dr. Adusumilli sees patients at Memorial Sloan Kettering Cancer Center in New York City. He holds many professional titles at the hospital, one of which is Co-Director of the Mesothelioma Program. He teams with Dr. Marjorie Zauderer, who is the other Co-Director.

His other professional titles with Memorial Sloan Kettering are:

  • Deputy Chief of Thoracic Services
  • Vice Chair for Translational Research of the Department of Surgery
  • Head of Solid Tumors Cell Therapy in the Cellular Therapeutics Center

His clinical focuses include pleural mesothelioma, lung cancer, metastasis to the lung and tumors in the chest wall. His surgical expertise includes pleurectomy/decortication, video-assisted thoracic surgery and diagnostic laparoscopy.

Degree icon

Medical Degrees and Residencies

    • Medical Degree from Guntur Medical College in India
    • Residency in Surgery at Southampton University Hospitals in the United Kingdom
    • Residency in General Surgery at Maimonides Medical Center in Brooklyn, New York
    • Residency in General Surgery at Lenox Hill Hospital in New York City
    • Fellowship in Cardiothoracic Surgery at Maimonides Medical Center
    • Fellowship in Thoracic Surgery at Memorial Sloan Kettering Cancer Center
    • Fellowship in Cardiothoracic Surgery at University of Pittsburgh Medical Center
Accomplishments icon

Certifications and Memberships

    • Board-certified in General Surgery
    • Board-certified in Thoracic Surgery

Get Connected to Dr. Prasad Adusumilli

Get Connected to Dr. Prasad Adusumilli - Form Image

Dr. Adusumilli is one of the top surgeons and specialists for pleural mesothelioma. He is Co-Director of the mesothelioma program at one of the best cancer centers in the world, Memorial Sloan Kettering Cancer Center in New York City.

Why Choose Dr. Adusumilli?

  • 15 years of experience in thoracic oncology and surgery
  • Authored research articles on novel treatments
  • Performs aggressive P/D surgery and diagnostic procedures


Excellent Relationship With Patients

Dr. Adusumilli prides himself on soothing anxieties of patients when first meeting them. He says patients and family members are often “overwhelmed by finding a treatment” that will send cancer into remission and keep it from coming back.

“I take the time to explain the key factors that are driving the disease, possible treatment options, the risks and benefits and the expected short-term and long-term outcomes,” he says in his doctor bio on the Memorial Sloan Kettering Cancer Center website.

There’s a follow-up meeting to answer questions before “finalizing” the treatment plan. This is done to reassure patients they’re considering every option and that quality of life is a priority

Activity in Clinical Trials for Mesothelioma

Dr. Adusumilli also has a laboratory with an eye on tumor microenvironment studies. He searches for biomarkers able to detect cancer quickly. He also investigates gene therapies, immunotherapies and virotherapies as potential alternatives to mesothelioma chemotherapy.

He co-authored a study report on CAR T-cell therapy for mesothelioma. This type of immunotherapy-gene therapy combination is approved by the FDA for blood cancers. It’s still in testing for solid tumors. CAR T cells are genetically modified T cells extracted from the patient’s body and reprogrammed to find specific cancer proteins.

The trial led to a 100% safety tolerance with the CAR T-cell drug IcasM28z, which looks for the protein mesothelin. The therapy persisted in 39% of patients’ blood for 100 days after injection. When this cell therapy was paired with the immune checkpoint inhibitor pembrolizumab (Keytruda), the median survival was 24 months (two years).

He’s also leading another trial, with Dr. Zauderer, for mesothelioma. It gives patients the immunotherapy drug nivolumab (Opdivo) plus chemotherapy after surgery. Many cancer centers use chemotherapy and radiation after surgery. This is one of the first testing immunotherapy after surgery.

How to See Dr. Adusumilli for Your Mesothelioma Case

You can get in contact with Dr. Adusumilli, who is seeing new patients and cases of malignant mesothelioma. We urge you to use a patient advocate, who sometimes has direct access to the surgeons, medical oncologists and program navigators at the top cancer centers.

Our patient advocate, registered nurse Karen Ritter, can help you schedule an initial appointment with Dr. Adusumilli, or another doctor near where you live. Email Karen at karen@mesotheliomaguide.com to begin determining or adjusting your treatment goals.

Sources & Author

    1. Prasad S. Adusumilli, MD, FACS. Memorial Sloan Kettering Cancer Center. Retrieved from: https://www.mskcc.org/cancer-care/doctors/prasad-adusumilli. Accessed: 11/26/2021.
    2. The Prasad Adusumilli Lab. Memorial Sloan Kettering Cancer Center. Retrieved from: https://www.mskcc.org/research-areas/labs/prasad-adusumilli. Accessed: 11/26/2021.
    3. A Study of Nivolumab Immunotherapy and Chemotherapy followed by Surgery for Pleural Mesothelioma. Memorial Sloan Kettering Cancer Center. Retrieved from: https://www.mskcc.org/cancer-care/clinical-trials/19-272. Accessed: 11/26/2021.
    4. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discovery. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/34266984/. Accessed: 07/19/2021.
Devin Golden

About the Writer, Devin Golden

Devin Golden is a content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.